3 news items
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
STTK
14 May 24
results of Shattuck's preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
STTK
2 May 24
: plans for our preclinical studies, clinical trials and research and development programs; plans for expansion of clinical trials; the anticipated
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
STTK
9 Apr 24
and research and development programs; expectations regarding the timing, completion and outcome of the company's clinical trials; the unpredictable
- Prev
- 1
- Next